Trials / Unknown
UnknownNCT04275388
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 426 (estimated)
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 100 Years
- Healthy volunteers
- Not accepted
Summary
the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xiyanping injection | Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride, |
| DRUG | Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride | Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride |
Timeline
- Start date
- 2020-05-15
- Primary completion
- 2020-07-14
- Completion
- 2021-12-14
- First posted
- 2020-02-19
- Last updated
- 2020-05-20
Source: ClinicalTrials.gov record NCT04275388. Inclusion in this directory is not an endorsement.